GLPwatch
Papers (10410)
Page 150 of 174, ranked by citation count.
- Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers.
- Bile acid diarrhoea.
- In early Parkinson disease, daily subcutaneous lixisenatide reduced motor disability progression at 12 mo.
- Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study.
- Assessment of Thermal and Photolytic Stress Effects on the Stability of Primary Structure of Synthetic Liraglutide Using LC-HRMS/MS.
- [Oral semaglutide, first oral GLP-1 receptor agonist (Rybelsus®)].
- Analysis of the Efficacy of Polyenyl Phosphatidylcholine in Combination with Liraglutide in Nonalcoholic Fatty Liver Disease and the Effect of Omentin-1 and Vaspin Expression.
- Liraglutid verzögert Diabetesentstehung.
- New Injectable Drug for Type 2 Diabetes.
- Adultes en surpoids ou obèses : effets du sémaglutide.
- In brief: Removal of suicidality warning from GLP-1 Agonists for weight management.
- Semaglutide use in a patient with a long-term ileostomy: A case report highlighting clinical risks and evidence gaps.
- [Obesity treatment with semaglutide].
- Iixisenatide. Wait for conclusive results on complications of diabetes.
- Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea.
- Drug-Associated Ketoacidosis: A Comprehensive Disproportionality Analysis Based on the FAERS Database.
- Innovative Therapeutic Approaches Targeting Obesity: Can Flavonoids Improve the Efficacy of Anti-Obesogenic Drugs?
- NewDrugs 2017, part 2.
- A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses.
- The impact of nutrition, exercise, and pharmacotherapy on menstrual health in adolescents with overweight and obesity.
- Tirzepatide and metformin effects on hunger and BMI in an adolescent with hyperphagia and severe obesity due to MC4R Deficiency: a case report.
- Cost-Effectiveness of Tirzepatide for the Management of Heart Failure With Preserved Ejection Fraction and Obesity.
- HIPPOCAMPAL GANGLIOSIDE COMPOSITION IS ALTERED BY METFORMIN AND LIRAGLUTIDE TREATMENT IN A HIGH-FAT HIGH-SUGAR DIET RAT MODEL.
- Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.
- Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland.
- Oral semaglutide (Wegovy) for weight loss.
- Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study.
- [Role of exendin-4 in cardiovascular diseases].
- Health-Related Quality of Life and Work-Related Outcomes in People with Obesity or Overweight Treated with Tirzepatide or Other Obesity Medications: United States Results from the Adelphi Real World Obesity Disease Specific Programme™.
- Appetite, Obesity, Metabolism, and Malignancy: Do Incretin-Mimetic Drugs Reduce Cancer Risk?
- [Nephroprotection in patients with diabetes mellitus].
- In patients with type 2 diabetes and high CV risk, liraglutide reduced a composite CV outcome at a median 3.8 y.
- Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice.
- Semaglutide Once Weekly Helps Adolescents Lose Weight, but 4% Developed Acute Cholelithiasis.
- Real world, retrospective experience of glucagon-like peptide-1 receptor agonists in kidney transplant recipients: A single-center case series.
- [Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBYII study (observations lasting 24 months)].
- Effect of tirzepatide on prediabetics and blood pressure with implications for future research.
- Real-World Effectiveness and Safety of Tirzepatide, Semaglutide, and Liraglutide in Adults with Overweight or Obesity without Diabetes: A Comparative Study.
- Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety.
- [Does a higher dose of oral semaglutide treatment make sense?]
- Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events.
- Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.
- Beyond weight loss: How metabolism in human adipocytes is shaped by GLP-1R agonists and dual GIPR/GLP-1R agonists.
- Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
- Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).
- Tirzepatide-induced Weight Loss in Overweight or Obese Midlife Adults with and without Type 2 Diabetes: A Real-world Comparative Cohort Study.
- Study on chitosan/carrageenan core-shell nanoparticles for oral co-administration of insulin/exenatide enhance insulin secretion in type 2 diabetes.
- Impact of liraglutide on albumin-to-creatinine ratio in type 2 diabetes mellitus: a meta-analysis.
- Effects of acute GLP-1 analogue infusion on the glycemic and neurohormonal responses to meal test in non- hypoglycemic subjects after gastric bypass.
- [Prescribing semaglutide for overweight: is it allowed?]
- A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide.
- Anatomical evidence links the stomach to the central amygdala, a region responsive to local GLP-1R agonist induced feeding and nausea-like behaviors in male mice.
- [The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy].
- Cardiovascular efficacy of tirzepatide: what real-world evidence promises.
- Crowdsourcing-Based Knowledge Graph Construction for Drug Side Effects Using Large Language Models with an Application on Semaglutide.
- Choice of first injectable therapy in type 2 diabetes.
- Effects of insulin and exenatide therapy on glycemic control and β-cell function in patients newly diagnosed with type 2 diabetes and severe hyperglycemia.
- Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial.
- An experimental medicine protocol for exploring the haemodynamic effects of dual agonism at the glucagon-like peptide-1 and glucagon receptor in healthy subjects.
- Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.